Aim Immunotech Inc. · AMEX:AIM
Aim Immunotech — 3rd Marie Sklodowska-Curie Symposium on Cancer Research and Care 2023
16 slides from Aim Immunotech's conference presentation, Sep 22, 2023
Slide 1: Rintatolimod (Ampligen): Overview of Ampligen's Clinical Progress in Oncology
NYSE American: AIM AIMIMMUNO.COM Phone: 352-448-7797 Rintatolimod (Ampligen®): Overview of Ampligen's Clinical Progress in Oncology Christopher McAleer, Ph.D. Science Officer, AIM ImmunoTech Email: info@aimimmuno.com 3" Marie Sklodowska-Curie Symposium on Cancer Research and Care September 20-224, 2
Slide 2: Ampligen (Rintatolimod) Mechanism of Action
Ampligen (Rintatolimod) Mechanism of Action Activated TLR3 Homodimer ; ool cy iy Ampligen is a synthetic dsRNA and activator of TLR3 Ampligen is unique amongst TLR agonists in its mechanism of action, specificity and safety profile Only known TLR agonist to avoid the systemic inflammatory MyD88 path
Slide 3: The Immunological Activity of Ampligen has been Demonstrated in a Wide Body of Literature
The Immunological Activity of Ampligen has been Demonstrated in a Wide Body of Literature Reference(s)* Theodoraki, et al. (2018) Zarling, et al. (1980) Kalinski, et al. (2016) Overton, et al. (2014) Nicodemus, et al. (2010) a _ _ sient aN Theodoraki, et al. (2018); : eff-attracting chemokine (CXC e
Slide 4: The Immunological Activity of Ampligen has been Demonstrated in a Wide Body of Literature — cont'd
The Immunological Activity of Ampligen has been Demonstrated in a Wide Body of Literature — cont'd Reference(s)* Navabi, et al. (2009) reading and cross-protective immunity in mice Ichinohe, et al. (2007) rsensitivity (DTH) response in HIV disease Thompson, et al. (1996) otoxicit Hubbell, et al. (19
Slide 5: Ampligen Induces Dendritic Cell Maturation and Enhances T-cell Activation
Ampligen Induces Dendritic Cell Maturation and Enhances T-cell Activation Increased IL-12, HLA Class 1 and II, CD83, CD86, CD40, CCR7 = - —— Pe cbD14 CD86 Class Il CD40 z o ao, eons] 8 0% |[8) 06% |B 51% | — isotype aren I jz 2m — Antibody ELI \ B 1000 oat, & mo Sa STOTERL | [PTT] [RU TOTONO| PARNER
Slide 6: Ampligen Induces Dendritic Cell Maturation and Enhances T-cell Activation
Ampligen Induces Dendritic Cell Maturation and Enhances T-cell Activation OTNFa/FNa 1m PolylC,,U Lalit LAD IL-2 (p70) IFNy = MCPAMIP-ta TNF-a. Above: Supernatants from dendritic cell cultures that were matured with polyl:C,,U (25 ug/ml) or TNF-a/IFN-a were assayed for a panel of cytokines by Multipl
Slide 7: Ampligen Increases NK and Mo Activity
Ampligen Increases NK and Mo Activity NK Activity Mo antitumor activity * * * * * * o 1 2 4 8 ° 1 2 4 8 Ampligen (mg/kg) Ampligen (mg/kg) geese % Lysis LL target 5 © Be a g = a x Dose - response effect of Ampligen on splenic NK activity and peritoneal Md antitumor activity. * p < 0.05 7 Sam https://
Slide 8: Priority Oncology Pipeline
Priority Oncology Pipeline Indications Pancreatic: Approach Ampligen* Following. Preclinical Phase1 Phase 2 Highlights Patient Recruitment Ongoing =o Locally Advanced Adenocarcinoma _| FOLFIRINOX Pancreati Single Agent Early Access Program Late-Stage; Early Access Program : == v 8 Pancre: ‘Ampligen®
Slide 9: Promising Late-Stage Pancreatic Cancer Results From Early Access Program (EAP) Published in Cancers
Promising Late-Stage Pancreatic Cancer Results From Early Access Program (EAP) Published in Cancers Statistically Significant Increased Overall Survival Compared to Historical Controls in Treatment of Late-Stage Pancreatic Cancer Survival Data: Median overall survival (OS) was 19 months in the Ampli
Slide 10: Ampligen Maintenance Therapy after FOLFIRINOX Improves Overall and Progression-Free Survival
Ampligen Maintenance Therapy after FOLFIRINOX Improves Overall and Progression-Free Survival Overall survival 100) —L— Rintatolimod —L— Rintatolimod —L— Subset matched controls —L— Subset matched controls g SS £2 so. 8 50 ° o 0 12 24 36 oO 12 24 36 48 Time in months since start FOLFIRINOX Time in mo
Slide 11: Long-Term Survivors Exhibit Decreased SIII and NLR as well as Increased B-Cell Counts
Long-Term Survivors Exhibit Decreased SIIl and NLR as well as Increased B-Cell Counts (A) (B) (C) si NLR B-Cells ‘Systemic Immune Inflammation Index 3 8 3 8 Neutrophils to Lymphocytes Ratio Kr | * Counts per microLiter Bg 8 8 CG C—= m—~— (A) Systemic immune inflammation Index (Stl), uw (@) Neu lymph
Slide 12: Patients With a SIII <1000 Respond Better to Ampligen Treatment
Patients With a SIIl <1000 Respond Better to Ampligen Treatment Overall survival Overall survival: SIIl comparison (N=57) + All (N=27) + Historical Control (N=27) +. Original Subset {(N=49) +. <4000 (N=8) + >=1000 (N=27) Historical Control = S = oS Ss 1 Probability of Survival a s Probability of Sur
Slide 13: Pancreatic Cancer Clinical Trials
Pancreatic Cancer Clinical Trials Collaboration between Erasmus MC and Astra Zeneca Cet Astrazeneca Combinatorial therapy of Ampligen and valumab following FOLFIRINOX in patients with metastatic pancreas cancer
Slide 14: Clinical Safety Record of Ampligen (dsRNA)
Clinical Safety Record of Ampligen (dsRNA) cine oO FDA Generally well-tolerated, with Serious adverse event (SAE) No evidence FDA Advisory Committee approximately 100,000 IV doses | profile shows no clinically oFautoinmanity voted in majority that the administered in humans significant differences s
Slide 15: Conclusion
Conclusion Ampligen mun im with fe)
Slide 16: Christopher McAleer, Ph.D.
NYSE American: AIM Christopher McAleer, Ph.D. Scientific Officer, AIM ImmunoTech Email: info@aimimmuno.com Phone: 352-448-7797 AlMImmuno.com
AIM ImmunoTech — 3rd Marie Sklodowska-Curie Symposium on Cancer Research and Care 2023 on 6ix